抗体药物偶联物 (ADC) 是一类新兴的肿瘤治疗方法，它将单克隆抗体的靶标特异性与细胞毒性有效负载相结合。这些药物具有独特的皮肤毒性，不同药物的毒性不同。目前，有 11 种 ADC 获得监管部门批准用于治疗实体瘤和液体肿瘤，超过 80 种 ADC 目前正处于临床开发阶段，皮肤科医生认识并适当减轻与这些疗法相关的皮肤毒性至关重要。本临床综述将总结已批准 ADC 的新机制和适应症，讨论临床试验和上市后研究中显示的皮肤毒性，并在遇到这些反应时提供识别和管理指导，以帮助患者保持安全、舒适的用药。版权所有 © 2024 年。由爱思唯尔公司出版。

Antibody-drug conjugates (ADCs) are a new and emerging category of oncologic treatments that combine the target specificity of a monoclonal antibody with a cytotoxic payload. These drugs are associated with unique cutaneous toxicities that vary across agents. Currently, there are eleven ADCs with regulatory approval for solid and liquid tumors and over 80 ADCs currently in clinical development, it is critical for dermatologists to recognize and appropriately mitigate the cutaneous toxicities associated with these therapies. This clinical review will summarize the novel mechanisms and indications of approved ADCs, discuss dermatologic toxicities demonstrated in clinical trials and post-marketing studies, and impart recognition and management guidance when encountering these reactions to help maintain patients safely and comfortably on their medications.Copyright © 2024. Published by Elsevier Inc.